Project Title: Immunology and anti-invasive treatments for pancreatic cancer: a new therapeutic partnership
Principal Investigator: Dr Marina Pajic
Position Held: Group Leader, Personalised Cancer Therapeutics (since 2013) - Garvan Institute of Medical Research, The Kinghorn Cancer Centre
Project Summary: Dr. Pajic and her team identified 13 major subtypes of pancreatic cancer based on differences in the DNA of tumours. They aim to examine which of these tumour subtypes are most likely to respond to a novel combination therapy using targeted and individually promising agents, Ruxolitinib and Dasatinib. They believe their research is at the forefront of personalised medicine and ensures patients get the best treatment suited to their exact cancer.